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In patients with known or suspected coronary artery disease (CAD), the
standard of care is invasive management guided by coronary angiography
performed invasively or, increasingly, non-invasively by computed tomog-
raphy coronary angiography (CTCA).1 Imaging tests for coronary anatomy
and disease inform the diagnosis and treatment of coronary heart disease.
When obstructive CAD is identified, the standard of care is guideline-
directed medical therapy, including preventive medicines (antiplatelet,
statin, and angiotensin-converting enzyme inhibitor), angina therapy (beta-
blocker, calcium channel blocker, and nitrate), and revascularization using
percutaneous coronary intervention (PCI) with drug-eluting stent(s) or
coronary artery bypass graft (CABG) surgery.1 The decision for PCI or
CABG depends on CAD severity and clinical characteristics, notably age,
diabetes, and left ventricular ejection fraction (LVEF).
In 2007, the results from the Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation (COURAGE) trial in
2287 patients called out standard care.2–4 As an initial management strat-
egy in patients with stable CAD, PCI did not reduce the risk of death,
myocardial infarction (MI), or other major cardiovascular events when
added to optimal medical therapy. Subsequently, the trial was widely
criticized by many clinicians. Perceived limitations of the trial design pre-
dominated over its strengths and the standard approach for invasive
management did not change.
In light of the new evidence and controversy, the International Study of
Comparative Health Effectiveness with Medical and Invasive Approaches
(ISCHEMIA) was conceived by Judith S. Hochman, David J. Maron and
colleagues in the USA.5 The trial was funded by the National Heart Lung
and Blood Institute. ISCHEMIA compared a routine invasive strategy with
cardiac catheterization followed by revascularization plus optimal medical
therapy. The conservative strategy involved guideline-directed medical
therapy with coronary angiography and revascularization only indicated
for patients with acute coronary syndrome, ischaemic heart failure, resus-
citated cardiac arrest, or refractory symptoms. The primary composite
was cardiovascular death, MI, resuscitated cardiac arrest, or hospitaliza-
tion for unstable angina or heart failure. The main inclusion criteria were
at least moderate ischaemia on a qualifying stress test, willing to comply
with the protocol and written informed consent. The main exclusion cri-
teria were a LVEF <35%, a history of unprotected left main stenosis
>50%, a finding of ‘no obstructive CAD’ (<50% stenosis in all major epi-
cardial vessels) on prior CTCA or prior catheterization, performed
within 12 months, coronary anatomy unsuitable for either PCI or CABG,
unacceptable level of angina despite maximal medical therapy and an
acute coronary syndrome within the previous 2 months.
The ISCHEMIA trial results were recently reported at the Scientific
Sessions of the American Heart Association (16 November 2019)
(https://professional.heart.org/professional/ScienceNews/UCM_505226_
ISCHEMIA-Clinical-Trial-Details.jsp). After 3.3 years of follow-up,
there was no difference in the primary endpoint between the random-
ized groups. There was no heterogeneity of treatment effect, including
by stress test, extent of ischaemia or CAD. Interestingly, the event
curves for the primary endpoint cross at 2 years from randomiza-
tion: 2 in 100 higher estimated rate with invasive management at
6 months and 2 in 100 lower estimated rate with invasive manage-
ment at 4 years. Procedural MIs were increased in the invasive group
(reflecting the injurious effects of stenting and CABG surgery),
whereas spontaneous MIs were reduced with an invasive strategy
(reflecting the protective effects of stents and bypass grafts). Despite
high-risk clinical characteristics, including moderate-ischaemia and ex-
tensive CAD, all-cause mortality in both groups was relatively low
(6.4%), reflecting the generalized protective effects of guideline-
directed medical therapy. On the other hand, angina and quality of life
were improved in the invasive group (https://www.abstractsonline.
com/pp8/#!/7891/presentation/35080).
Sripal Bangalore and colleagues simultaneously reported the primary
results of the ISCHEMIA-Chronic Kidney Disease (ISCHEMIA-CKD)
(https://professional.heart.org/professional/ScienceNews/UCM_505227_
ISCHEMIA-CKD-Clinical-Trial-Details.jsp). The trial had a similar de-
sign focused to patients with Stage 4–5 chronic kidney disease.
ISCHEMIA-CKD demonstrated that, among 777 patients with stable
ischaemic heart disease and chronic kidney disease (53% on dialysis),
an initial invasive strategy did not improve clinical outcomes when
compared with an initial conservative strategy (death or MI: invasive
36.4%, conservative 36.7%, P= 0.95). Notably, the trial excluded highly
symptomatic patients and the invasive arm was associated with rela-
tively low rates of coronary revascularization.
We congratulate the ISCHEMIA leadership and acknowledge the fun-
ders. We applaud the investigators and their patients who supported the
trial. We sincerely acknowledge the participants who died or experi-
enced adverse events. Ischaemic heart disease persists as a leading cause
of premature death and disability worldwide,6 and this trial points to the
unmet medical need.
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ISCHEMIA has now been widely discussed. The results underline the
importance of strategies to prevent and treat atherosclerosis. The re-
duction in the primary endpoint from 2 to 4 years points to a potential
enduring benefit of revascularization in the longer term. A future report
will be needed to confirm or refute this possibility. The results indicate
that patients with anginal symptoms not controlled by medical therapy
should be considered for invasive management.
Scientists should pursue unanswered questions. What are the new or
unanswered questions for the basic science community in light of the
ISCHEMIA trial results? In our view, the following are persisting, clinically
relevant questions: is chronic myocardial ischaemia therapeutically modi-
fiable? Is chronic ischaemia the consequence and/or cause of microvascu-
lar dysfunction? Is microvascular dysfunction a common problem after
successful revascularization? Does persisting microvascular dysfunction
reduce the clinical effectiveness of PCI and/or CABG? If so, what are the
mechanisms underlying microvascular dysfunction, what treatments
might be disease-modifying and beneficial to patients? The clinical rele-
vance of microvascular dysfunction in patients with flow-limiting CAD is
being investigated in the DEFINE-FLOW study,7 due to be reported in
2020. The Changes in Ischemia and Angina Over 1 Year Among
ISCHEMIA Trial Screen Failures With no Obstructive CAD on
Coronary CT Angiography (CIAO) substudy will also be informative.8 In
considering these questions, we wish to highlight relevant publications in
Cardiovascular Research, including, ‘The many faces of myocardial ischae-
mia and angina’,9 vasculoprotection afforded by haematopoietic stem
cells,10 and other novel therapies.11
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